VetDC (www.vetdc.com), a Colorado State University startup company, is dedicated to bringing innovative pet cancer therapeutics to market. In addition to TANOVEA-CA1, the first FDA conditionally approved drug for the treatment of canine lymphoma, VetDC is developing VDC-597, a novel, dual-acting PI3K/mTOR inhibitor, for multiple veterinary cancers, such as hemangiosarcoma and osteosarcoma.
320 E. Vine Dr.
Suite 218
Fort Collins, Colorado 80524
(877) 468-3832
http://www.vet-dc.com